Neurocrine (NBIX) Stock: Why It Rose 15% and What's Next

Quick answer

Neurocrine Biosciences traded at $166.92 at 11:50am ET on Nov 3, 2026, up 14.8% from a $145.35 close, after its third-quarter net product sales passed $1 billion for the first time. The company reported after the close on Nov 2. Total revenue rose 41% to $1.123 billion from $795 million a year earlier, Ingrezza sales rose 17% to $801 million and the company raised its full-year Ingrezza guidance to $2.9 billion to $2.925 billion. The stock traded from $157 to $159.04 before the open, opened at $159, and climbed through the morning to $168.47 at 11:25am.

Our view: Bullish through December 15, 2026, when Neurocrine holds its R&D Day in New York and is expected to update its Phase 3 programs. The case for the stock: Ingrezza is still growing at double-digit volume nine years after its 2017 approval, Crenessity more than doubled in a year to $211 million a quarter, Vykat XR added $107 million in its first full quarter, non-GAAP earnings rose 52% to $3.29 a share, and the average analyst target of $204.78 is 23% above the price, with the lowest target at $165. The case against: the company says about $20 million of the quarter came from order timing that should reverse in the fourth quarter, cash fell to $790 million after the Soleno deal, operating expenses rose 42%, and an RSI near 78 says the stock is stretched in the short run. We think the case for carries more weight, because the guidance raise came from demand rather than price and the R&D Day is a known date with two late-stage programs to discuss. We would move off Bullish if the stock closes back below $158, the bottom of today's opening range, if weekly Ingrezza prescriptions slow, or if the R&D Day moves the osavampator or direclidine timelines later. This is a view on direction over that window, not a recommendation to trade the stock.

Neurocrine Biosciences daily closing price from Sep 21 to Nov 3, 2026, with the Oct 13 low, the Oct 26 recovery and the Nov 3 earnings gap marked

Key takeaways

Neurocrine Biosciences traded at $166.92 at 11:50am ET on Nov 3, 2026, up 14.8% from a $145.35 close, after third-quarter net product sales passed $1 billion for the first time. It reached $168.47 at 11:25am.
Total revenue rose 41% to $1.123 billion from $795 million, and non-GAAP earnings rose to $3.29 a share from $2.17.
Ingrezza sales rose 17% to $801 million and full-year Ingrezza guidance went up to $2.9 billion to $2.925 billion from $2.825 billion to $2.875 billion. Crenessity sales more than doubled to $211 million.
Vykat XR, the Prader-Willi drug that came with the Soleno acquisition in May, added $107 million. The deal took cash and securities down to $790 million from $2.543 billion at the end of 2025.
Our view is Bullish through December 15, 2026, when Neurocrine holds its R&D Day: three growing drugs now carry the company, and the average analyst target of about $205 sits well above the price.

Table of contents

Nov 3, 2026: sales pass $1 billion and Ingrezza guidance goes up
The numbers
The bull case
The risks
What comes next

Nov 3, 2026: sales pass $1 billion and Ingrezza guidance goes up

Neurocrine closed Nov 2 at $145.35, little changed over the prior week. It reported after that close, and premarket trading ranged from $157.00 to $159.04. The stock opened at $159.00, its low of the session was $157.91 in the first minute, and it rose steadily to $168.47 at 11:25am. At 11:50am it was $166.92, up 14.8%, on about 1.8 million shares.

What moved the stock:

The guide for the largest drug went up. Ingrezza, which treats tardive dyskinesia and Huntington's chorea, sold $801 million, up 17%, with double-digit volume growth and record total and new prescriptions. Full-year guidance rose to $2.9 billion to $2.925 billion from $2.825 billion to $2.875 billion, about $60 million higher at the midpoint.
The second and third drugs are now large. Crenessity, for congenital adrenal hyperplasia, sold $211 million, up from $98 million, with about 80% of dispensed prescriptions reimbursed. Vykat XR sold $107 million.
Earnings grew faster than revenue. Non-GAAP earnings were $3.29 a share against $2.17 a year earlier. GAAP earnings were $1.96 against $2.04, because of Soleno acquisition costs and amortization.
The group helped a little. The SPDR S&P Biotech ETF was up 2.4%, Acadia up 1.4% and Teva, which sells the rival tardive dyskinesia drug Austedo, up 4.3% late in the morning.

At 11:50am RSI(14) was 78, overbought, and the stock was 16.9% above its 20-day average, 14.0% above its 50-day and 13.3% above its 200-day average. The 52-week high is $186.12.

Bar chart of Neurocrine third-quarter 2026 net product sales by drug: Ingrezza $801 million, Crenessity $211 million, Vykat XR $107 million

The numbers

Measure	Q3 2026	Year earlier	Change
Total revenue	$1,123 million	$795 million	+41%
Ingrezza net sales	$801 million	$687 million	+17%
Crenessity net sales	$211 million	$98 million	+115%
Vykat XR net sales	$107 million	none	new
Non-GAAP diluted EPS	$3.29	$2.17	+52%
GAAP diluted EPS	$1.96	$2.04	-4%
Cash and securities	$790 million	$2,543 million at Dec 31, 2025	-69%

Expenses rose with the larger business. Total operating expenses were $791.4 million against $555.9 million, and non-GAAP selling, general and administrative expense rose to $327 million from $259 million, after the company expanded its Ingrezza and Crenessity sales teams in the first quarter and took on Soleno's commercial staff. Research spending rose as the osavampator Phase 3 program in major depressive disorder and the direclidine Phase 3 program in schizophrenia advanced. The Soleno deal put about $2.2 billion of Vykat XR intellectual property on the balance sheet, which will be amortized over 16 years and will keep GAAP earnings below non-GAAP earnings for a long time.

The bull case

Neurocrine used to be a one-drug company, and that was the main worry about it. It is not anymore. Ingrezza is about 72% of product sales and still growing, while Crenessity and Vykat XR add about $1.3 billion a year at their third-quarter run rates. Our guide to why guidance changes move stocks explains why a raise in the second half of the year, when the company has most of the year's data, tends to carry more weight than one in the spring.

The pipeline is the second part of the case. Neurocrine is running two Phase 3 programs in large psychiatric markets, and the R&D Day on Dec 15 is the next chance to hear their timelines. Our page on how Phase 3 readouts move stocks covers why the run-up to a pipeline event can matter as much as the data itself. Even after a 15% gain the stock is 10% below its 52-week high.

The risks

Part of the quarter will not repeat. MarketBeat's summary of the call says management flagged about $20 million of benefit from order timing that it expects to reverse in the fourth quarter, so the next report will look slower than this one. Cash and securities fell by about $1.75 billion in nine months, mostly to buy Soleno, which leaves less room for another deal without borrowing.

Ingrezza also faces competition from Teva's Austedo in tardive dyskinesia, and the drug's growth will slow as it ages. A one-day gain of this size often gives some of it back before the next catalyst, and our page on post-earnings announcement drift explains when a gap tends to keep going and when it fades.

What comes next

The next dated event is the R&D Day in New York on December 15, 2026, followed by the fourth-quarter report, which analysts expect around February 10, 2027, with earnings of about $2.05 a share on $1.091 billion of revenue. Between now and then, the signals that matter are weekly Ingrezza prescription trends, any update on the Phase 3 timelines, and whether the stock holds the $158 level where it opened. Our page on what an investor day is explains what companies usually disclose at these events, and the rest of the session's movers are in today's biggest stock moves.

Frequently asked questions

Why did Neurocrine stock rise on Nov 3, 2026?

Neurocrine rose 14.8% to $166.92 at 11:50am ET on Nov 3 after it reported third-quarter results after the close on Nov 2. Net product sales passed $1 billion for the first time, total revenue rose 41% to $1.123 billion, and the company raised its full-year guidance for Ingrezza, its largest drug, to $2.9 billion to $2.925 billion.

How fast is Ingrezza growing?

Ingrezza third-quarter net sales were $801 million, up 17% from $687 million a year earlier, with double-digit volume growth and record total and new prescriptions, the company said. The new full-year guide of $2.9 billion to $2.925 billion compares with $2.825 billion to $2.875 billion before.

What are Crenessity and Vykat XR?

Crenessity treats congenital adrenal hyperplasia, a rare hormone disorder, and its sales rose 115% to $211 million in the quarter. Vykat XR treats hyperphagia in Prader-Willi syndrome and came with the Soleno Therapeutics acquisition, which closed in May 2026; it sold $107 million in the quarter.

Why did Neurocrine's GAAP earnings fall when revenue rose 41%?

GAAP earnings were $1.96 a share against $2.04 a year earlier because operating expenses rose to $791.4 million from $555.9 million, including Soleno acquisition costs, amortization of the roughly $2.2 billion of Vykat XR intellectual property, and higher research spending. Non-GAAP earnings, which exclude those items, rose to $3.29 from $2.17.

What is Dombey's view on Neurocrine stock?

Bullish through December 15, 2026, when Neurocrine holds its R&D Day in New York. This is a view on direction over that window, not a recommendation to trade the stock.

What would change the view on Neurocrine?

We would move off Bullish if the stock gives back the gap and closes below its $158 opening range, if weekly Ingrezza prescriptions slow before the R&D Day, or if the R&D Day pushes the osavampator or direclidine Phase 3 timelines later.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published November 3, 2026 · 5 min read · Event-Driven Investing